Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1989 2
1991 2
1992 2
1995 1
1996 3
1997 2
1999 2
2000 1
2002 2
2004 2
2005 7
2006 2
2008 1
2009 2
2010 3
2011 6
2012 5
2013 6
2014 7
2015 7
2016 6
2017 10
2018 13
2019 8
2020 5
2021 3
Text availability
Article attribute
Article type
Publication date

Search Results

98 results
Results by year
Filters applied: . Clear all
Page 1
Niraparib plus bevacizumab versus niraparib alone for platinum-sensitive recurrent ovarian cancer (NSGO-AVANOVA2/ENGOT-ov24): a randomised, phase 2, superiority trial.
Mirza MR, Åvall Lundqvist E, Birrer MJ, dePont Christensen R, Nyvang GB, Malander S, Anttila M, Werner TL, Lund B, Lindahl G, Hietanen S, Peen U, Dimoula M, Roed H, Ør Knudsen A, Staff S, Krog Vistisen A, Bjørge L, Mäenpää JU; AVANOVA investigators. Mirza MR, et al. Among authors: avall lundqvist e. Lancet Oncol. 2019 Oct;20(10):1409-1419. doi: 10.1016/S1470-2045(19)30515-7. Epub 2019 Aug 29. Lancet Oncol. 2019. PMID: 31474354 Clinical Trial.
The European Society of Gynaecological Oncology/European Society for Radiotherapy and Oncology/European Society of Pathology guidelines for the management of patients with cervical cancer.
Cibula D, Pötter R, Planchamp F, Avall-Lundqvist E, Fischerova D, Haie Meder C, Köhler C, Landoni F, Lax S, Lindegaard JC, Mahantshetty U, Mathevet P, McCluggage WG, McCormack M, Naik R, Nout R, Pignata S, Ponce J, Querleu D, Raspagliesi F, Rodolakis A, Tamussino K, Wimberger P, Raspollini MR. Cibula D, et al. Among authors: avall lundqvist e. Radiother Oncol. 2018 Jun;127(3):404-416. doi: 10.1016/j.radonc.2018.03.003. Epub 2018 May 1. Radiother Oncol. 2018. PMID: 29728273
The European Society of Gynaecological Oncology/European Society for Radiotherapy and Oncology/European Society of Pathology Guidelines for the Management of Patients With Cervical Cancer.
Cibula D, Pötter R, Planchamp F, Avall-Lundqvist E, Fischerova D, Haie Meder C, Köhler C, Landoni F, Lax S, Lindegaard JC, Mahantshetty U, Mathevet P, McCluggage WG, McCormack M, Naik R, Nout R, Pignata S, Ponce J, Querleu D, Raspagliesi F, Rodolakis A, Tamussino K, Wimberger P, Raspollini MR. Cibula D, et al. Among authors: avall lundqvist e. Int J Gynecol Cancer. 2018 May;28(4):641-655. doi: 10.1097/IGC.0000000000001216. Int J Gynecol Cancer. 2018. PMID: 29688967
A phase I study of the PARP inhibitor niraparib in combination with bevacizumab in platinum-sensitive epithelial ovarian cancer: NSGO AVANOVA1/ENGOT-OV24.
Mirza MR, Bergmann TK, Mau-Sørensen M, Christensen RD, Åvall-Lundqvist E, Birrer MJ, Jørgensen M, Roed H, Malander S, Nielsen F, Lassen U, Brøsen K, Bjørge L, Mäenpää J. Mirza MR, et al. Among authors: avall lundqvist e. Cancer Chemother Pharmacol. 2019 Oct;84(4):791-798. doi: 10.1007/s00280-019-03917-z. Epub 2019 Aug 2. Cancer Chemother Pharmacol. 2019. PMID: 31375879 Clinical Trial.
The European Society of Gynaecological Oncology/European Society for Radiotherapy and Oncology/European Society of Pathology Guidelines for the Management of Patients with Cervical Cancer.
Cibula D, Pötter R, Planchamp F, Avall-Lundqvist E, Fischerova D, Haie-Meder C, Köhler C, Landoni F, Lax S, Lindegaard JC, Mahantshetty U, Mathevet P, McCluggage WG, McCormack M, Naik R, Nout R, Pignata S, Ponce J, Querleu D, Raspagliesi F, Rodolakis A, Tamussino K, Wimberger P, Raspollini MR. Cibula D, et al. Among authors: avall lundqvist e. Virchows Arch. 2018 Jun;472(6):919-936. doi: 10.1007/s00428-018-2362-9. Epub 2018 May 4. Virchows Arch. 2018. PMID: 29725757
Clinical trials in recurrent ovarian cancer.
Friedlander M, Trimble E, Tinker A, Alberts D, Avall-Lundqvist E, Brady M, Harter P, Pignata S, Pujade-Lauraine E, Sehouli J, Vergote I, Beale P, Bekkers R, Calvert P, Copeland L, Glasspool R, Gonzalez-Martin A, Katsaros D, Kim JW, Miller B, Provencher D, Rubinstein L, Atri M, Zeimet A, Bacon M, Kitchener H, Stuart GC; Gynecologic Cancer InterGroup. Friedlander M, et al. Among authors: avall lundqvist e. Int J Gynecol Cancer. 2011 May;21(4):771-5. doi: 10.1097/IGC.0b013e31821bb8aa. Int J Gynecol Cancer. 2011. PMID: 21543939 Review.
High density of stroma-localized CD11c-positive macrophages is associated with longer overall survival in high-grade serous ovarian cancer.
Corvigno S, Mezheyeuski A, De La Fuente LM, Westbom-Fremer S, Carlson JW, Fernebro J, Åvall-Lundqvist E, Kannisto P, Hedenfalk I, Malander S, Rolny C, Dahlstrand H, Östman A. Corvigno S, et al. Among authors: avall lundqvist e. Gynecol Oncol. 2020 Dec;159(3):860-868. doi: 10.1016/j.ygyno.2020.09.041. Epub 2020 Oct 5. Gynecol Oncol. 2020. PMID: 33032823
Primary treatment patterns and survival of cervical cancer in Sweden: A population-based Swedish Gynecologic Cancer Group Study.
Bjurberg M, Holmberg E, Borgfeldt C, Flöter-Rådestad A, Dahm-Kähler P, Hjerpe E, Högberg T, Kjølhede P, Marcickiewicz J, Rosenberg P, Stålberg K, Tholander B, Hellman K, Åvall-Lundqvist E. Bjurberg M, et al. Among authors: avall lundqvist e. Gynecol Oncol. 2019 Nov;155(2):229-236. doi: 10.1016/j.ygyno.2019.08.022. Epub 2019 Aug 30. Gynecol Oncol. 2019. PMID: 31477283
98 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page